{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:39:34Z","timestamp":1784173174635,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41375-021-01466-0","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T08:03:29Z","timestamp":1636358609000},"page":"3585-3588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group"],"prefix":"10.1038","volume":"35","author":[{"given":"Anne Mea","family":"Spanjaart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-3245","authenticated-orcid":false,"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-5779","authenticated-orcid":false,"given":"Rafael","family":"de La Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tridello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Ortiz-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1038-5197","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7774","authenticated-orcid":false,"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-0929","authenticated-orcid":false,"given":"Friso","family":"Calkoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3924-8578","authenticated-orcid":false,"given":"Pim","family":"Mutsaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Giannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6585-9586","authenticated-orcid":false,"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Pinho","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Metafuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona L.","family":"Dignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Folber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-220X","authenticated-orcid":false,"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Knelange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kroger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-6021","authenticated-orcid":false,"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"1466_CR1","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881\u201392.","journal-title":"Blood."},{"key":"1466_CR2","doi-asserted-by":"publisher","unstructured":"Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021. https:\/\/doi.org\/10.1038\/s41375-021-01302-5.","DOI":"10.1038\/s41375-021-01302-5"},{"key":"1466_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2352-3026(20)30429-4","volume":"8","author":"A Sharma","year":"2021","unstructured":"Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:185\u201393.","journal-title":"Lancet Haematol"},{"key":"1466_CR4","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","volume":"383","author":"T Aydillo","year":"2020","unstructured":"Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586\u20138.","journal-title":"N Engl J Med"},{"key":"1466_CR5","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1172\/JCI141777","volume":"130","author":"GL Shah","year":"2020","unstructured":"Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Investig. 2020;130:6656\u201367.","journal-title":"J Clin Investig"},{"key":"1466_CR6","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1093\/cid\/ciab072","volume":"73","author":"MK Hensley","year":"2021","unstructured":"Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, et al. Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study. Clin Infect Dis. 2021;73:e815\u201321.","journal-title":"Clin Infect Dis"},{"key":"1466_CR7","doi-asserted-by":"publisher","first-page":"796.e1","DOI":"10.1016\/j.jtct.2021.07.005","volume":"27","author":"MU Mushtaq","year":"2021","unstructured":"Mushtaq MU, Shahzad M, Chaudhary SG, Luder M, Ahmed N, Abdelhakim H, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients. Transplant Cell Ther. 2021;27:796.e1\u20137.","journal-title":"Transplant Cell Ther"},{"key":"1466_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ajh.26209","volume":"96","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934\u201344.","journal-title":"Am J Hematol"},{"key":"1466_CR9","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1097\/HS9.0000000000000538","volume":"5","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere. 2021;5:e538.","journal-title":"Hemasphere"},{"key":"1466_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280\u20139.","journal-title":"Nat Med"},{"key":"1466_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s43018-021-00191-y","volume":"2","author":"A Thakkar","year":"2021","unstructured":"Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Pradip Shah A, et al. Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer. 2021;2:392\u20139.","journal-title":"Nat Cancer"},{"key":"1466_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med. 2021;385:562\u20136.","journal-title":"N Engl J Med"},{"key":"1466_CR13","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","volume":"184","author":"D Corti","year":"2021","unstructured":"Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 2021;184:3086\u2013108.","journal-title":"Cell"},{"key":"1466_CR14","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis K, \u0160ablauskas K, Ringelevi\u010di\u016bt\u0117 U, Vaitek\u0117nait\u0117 V, \u010cekauskien\u0117 R, Kry\u017eauskait\u0117 L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583\u201392.","journal-title":"Lancet Haematol"},{"key":"1466_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031\u20133.","journal-title":"Cancer Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01466-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T17:17:13Z","timestamp":1638292633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01466-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01466-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no financial support for this work that could have influenced the outcomes described in the paper. However, particular authors report a potential competing interests, which is described below. VOM has received compensation for travel support from Kite\/Gilead, Novartis, BMS\/Celgene, Takeda and Janssen and consultant or advisory fees from Kite\/Gilead, Novartis, BMS\/Celgene and compensation for presentations from Kite\/Gilead. PB has received honoraria from Amgen, BMS, Gilead, Incyte, Miltenyi Biotec, Novartis and Pfizer and funding from the Carlos III Health Institute FIS16\/01433 and 20\/00197, Asociaci\u00f3n Espa\u00f1ola contra el C\u00e1ncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). MK has received consultancy fees and honoraria from Novartis, BMS\/Cellgene, Kite\/Gilead, and Pfizer. PS has received honoraria from Kite\/Gilead, Novartis, and Chugai. RDB has received honoraria\/hospitality from Gilead, Novartis, and Janssen. CT has received consultancy fees, advisory fees and honoraria from Novartis, BMS\/Celgene, Roche, Janssen, Takeda, Kite\/Gilead, Incyte and research funding from Roche and travel expenses from Novartis, BMS\/Celgene, Roche, Janssen, Kite\/Gilead. PM has received research funding from Astra Zeneca and consultancy fees from BMS\/Celgene. EN has received research funding from Kite\/Gilead, advisory board fees for Novartis and BMS\/Celgene, travel support from Novartis and Kite\/Gilead, speaker fees from Kite\/Gilead. JML has received consultancy fees from Janssen, BMS, Novartis, Incyte, Roche, GSK and Pfizer and research funding from Roche, Novartis, Incyte, Astellas, and BMS. JMR received consultancy and speaker fees from Pfizer, Amgen, Shire, Ariad, Takeda and Novartis and research funding from Phizer, Amgen, Ariad, and Takeda. RS has received speakers fees and honoraria from Kite\/Gilead and Novartis. AB has received honoraria from Kite\/Gilead and Novartis. FA has received research funding from Mallinckrodt\/ThekarosHonoraria from Novartis, BMS\/Celgene, Janssen, Takeda, Mallinckrodt\/Thekaros, Kite\/Gilead, and Miltenyi Biomedicine. NK has received a research grant and honoraria from Novartis, Kite\/Gilead, and BMS. SM has received funding from Celgene\/BMS: Speakers bureau (via my institution); Novartis: Speakers bureau (via my institution); Gilead\/Kite: Other: Travel support, Expert panel (via my institution); DNA Prime SA and funding from Speakers bureau (via my institution); Miltenyi: Other: Data safety monitoring board (via my institution) Immunicum: Other: Data safety monitoring board (via my institution). MJK has received research funding from Kite\/Gilead and compensation for advisory boards and presentations and\/or travel support from Kite\/Gilead, Novartis, BMS\/Celgene, and Miltenyi Biotec (to institution).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}